Get the Stockscreener App
30.63
0.84%
-0.26
Pharvaris Nv stock is traded at $30.63, with a volume of 138.76K.
It is down -0.84% in the last 24 hours and down -19.44% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
See More
Previous Close:
$30.89
Open:
$30.68
24h Volume:
138.76K
Relative Volume:
0.21
Market Cap:
$2.15B
Revenue:
Net Income/Loss:
$-195.21M
P/E Ratio:
-9.6433
EPS:
-3.1763
Net Cash Flow:
$-176.19M
1W Performance:
-1.57%
1M Performance:
-19.44%
6M Performance:
+9.86%
1Y Performance:
+38.79%
1-Day Range:
$30.20
$31.20
1-Week Range:
$30.30
$32.32
52-Week Range:
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
30.63 | 2.15B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
490.56 | 124.34B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.75 | 85.74B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
752.60 | 77.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.22 | 50.51B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
191.28 | 41.00B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-26 | Initiated | Wells Fargo | Overweight |
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Singapore
Pharvaris N.V. (PHVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet - GlobeNewswire Inc.
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance UK
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy - GlobeNewswire Inc.
Pharvaris (PHVS) Shares Edge Higher, Holding Firmly Above Key SupportSMA Signal - siam.in
Form 4 Pharvaris N.V. For: 26 September By Investing.com - Investing.com Nigeria
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Canada
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com UK
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan
Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan
Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris (NASDAQ: PHVS) officer to sell 100,000 shares under Rule 144 - Stock Titan
Shareholder at Pharvaris (NASDAQ: PHVS) plans multi-million-dollar stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) lines up $10.5M sale of founder stock - Stock Titan
Pharvaris (NASDAQ: PHVS) director plans nearly $2M stock sale in 2026 - Stock Titan
Founder shares in Pharvaris (NASDAQ: PHVS) set for $765K planned sale - Stock Titan
Pharvaris (NASDAQ: PHVS) director lines up new stock sale after recent trades - Stock Titan
Pharvaris N.V. (PHVS) exec sells 46,400 shares in cashless trade - Stock Titan
Souverijns Wim Executes Option Exercises and Sells 26,090 Pharvaris Shares - Kalkine Media
Officer at Pharvaris (NASDAQ: PHVS) plans potential $1.77M stock sale - Stock Titan
Director in Pharvaris (PHVS) lines up new sale after $300K stock trade - Stock Titan
Pharvaris (NASDAQ: PHVS) CEO sells 2,291 shares in 10b5-1 plan trade - Stock Titan
Pharvaris (NASDAQ: PHVS) exec files to sell shares from vested stock and options - Stock Titan
2,291 Pharvaris (Nasdaq: PHVS) shares set for resale - Stock Titan
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com South Africa
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com UK
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pharvaris Nv Stock (PHVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Monges Viviane | Director |
Sep 23 '26 |
Sale |
33.05 |
11,969 |
395,524 |
5,500 |
| VIVIANE ROSINE FRANCOISE BECK | Director |
Sep 23 '26 |
Proposed Sale |
33.05 |
11,969 |
395,524 |
0 |
| Schikan Johannes Gerardus Chri | Director |
Sep 22 '26 |
Option Exercise |
20.00 |
800 |
16,000 |
115,967 |
| JOHANNES GER. CHRIS. PE SCHIKA | Director |
Sep 22 '26 |
Proposed Sale |
36.19 |
800 |
28,952 |
0 |
| Lu Peng | President |
Sep 22 '26 |
Option Exercise |
2.59 |
45,308 |
117,348 |
110,261 |
| Schikan Johannes Gerardus Chri | Director |
Sep 22 '26 |
Sale |
36.19 |
800 |
28,952 |
115,167 |
| DAVID NASSIF | Officer |
Sep 21 '26 |
Proposed Sale |
36.47 |
6,000 |
218,801 |
0 |
| Nassif David W. | CFO / CLO |
Sep 21 '26 |
Sale |
36.47 |
6,000 |
218,801 |
114,300 |
| ROBERT GLASSMAN | Director |
Sep 17 '26 |
Proposed Sale |
38.56 |
14,493 |
558,812 |
0 |
| GRAYMATTERS CONSULTING | Officer |
Sep 17 '26 |
Proposed Sale |
38.27 |
20,000 |
765,466 |
0 |
4.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):